Corrigendum: N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial (Ann Oncol (2010) 21 (493–497) DOI: 10.1093/annonc/mdp328);N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: A North Central Cancer Treatment Group (NCCTG) Trial

Annals of Oncology

Volumn 21, Issue 3, 2009, Pages 493-497

  Tan, W W ^a   Hillman, D W ^b   Salim, M ^c   Northfelt, D W ^d   Anderson, D M ^e   Stella, P J ^f   Niedringhaus, R ^g   Bernath, A M ^h   Gamini, S S ⁱ   Palmieri, F ^a   Perez, E A ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c Allan Blair Cancer Centre   (Canada)

^d MAYO CLINIC   (United States)

^e ABBOTT NORTHWESTERN HOSPITAL   (United States)

^f Michigan Cancer Research Consortium   (United States)

^g Missouri Valley Cancer Consortium ^*  (United States)

^h GEISINGER MEDICAL CENTER   (United States)

ⁱ MISSOURI VALLEY CANCER CONSORTIUM   (United States)

Author keywords

Adenocarcinoma; Breast neoplasms; Drug therapy; Neoplasm metastasis

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; IRINOTECAN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL;

EID: 77949649074     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdx811     Document Type: Erratum

References (19)

1. American Cancer Society. Overview: Breast Cancer. How Many Women Get Breast Cancer? Atlanta, GA: American Cancer Society, 2008; [about 6 screens] http://www.cancer.org/docroot/CRI/content/CRI_2_2_1X_How_many_people_get_breast_cancer_5.asp?sitearea= (26 Sep 2007, date last accessed).
2. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004; 100(1): 44-52.
3. Gennari A, Conte P, Rosso R et al. Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 2005; 104(8): 1742-1750.
4. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20(12): 2812-2823.
5. Perez EA, Hillman DW, Mailliard JA et al. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol 2004; 22(14): 2849-2855.
6. Frasci G, D'Aiuto G, Thomas R et al. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in anthracycline-paclitaxel-refractory breast cancer patients. Oncology 2005; 68(4-6): 391-397.
7. Stathopoulos GP, Tsavdaridis D, Malamos NA et al. Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol 2005; 56(5): 487-491.
8. Murad AM. Paclitaxel and gemcitabine as salvage treatment in metastatic breast cancer. Oncology (Williston Park) 2003; 17(12 Suppl 14): 26-32.
9. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007; 25(33): 5210-5217.
10. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26(24): 3950-3957.
11. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344(11): 783-792.
12. 2 as a second line chemotherapy in advanced breast cancer. Breast Cancer Res Treat 2002; 76 (Suppl 1): S88.
13. Sledge GW, Neuberg D, Bernardo P et al. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003; 21(4): 588-592.
14. Miles D, Vukelja S, Moiseyenko V et al. Survival benefit with capecitabine/docetaxel versus docetaxel alone: analysis of therapy in a randomized phase III trial. Clin Breast Cancer 2004; 5(4): 273-278.
15. Adjei AA, Klein CE, Kastrissios H et al. Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence of clinical activity. J Clin Oncol 2000; 18(5): 1116-1123.
16. Seneviratne L, Garcia A, Rogers M et al. Phase I clinical and pharmacokinetic (PK) trial of docetaxel (D) and irinotecan (I) administered on a weekly schedule [abstract]. Proc Am Soc Clin Oncol 2000; 19: 225.
17. Masuda N, Negoro S, Kudoh S et al. Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer. J Clin Oncol 2000; 18(16): 2996-3003.
18. Font A, Sanchez JM, Rosell R et al. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors. Lung Cancer 2002; 37(2): 213-218.
19. Bleickardt E, Argiris A, Rich R et al. Phase I dose escalation trial of weekly docetaxel plus irinotecan in patients with advanced cancer. Cancer Biol Ther 2002; 1(6): 646-651.